RXi Pharmaceuticals Corp (NASDAQ:RXII) was the recipient of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 424,241 shares, a decrease of 47.9% from the October 31st total of 814,036 shares. Based on an average daily volume of 2,666,716 shares, the short-interest ratio is presently 0.2 days.
Shares of NASDAQ RXII opened at $0.33 on Tuesday. The firm has a market capitalization of $1.45 million, a PE ratio of -0.08 and a beta of 2.07. RXi Pharmaceuticals has a 1 year low of $0.31 and a 1 year high of $7.70.
RXi Pharmaceuticals (NASDAQ:RXII) last announced its quarterly earnings data on Wednesday, November 14th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.04. The firm had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.05 million. RXi Pharmaceuticals had a negative net margin of 4,990.20% and a negative return on equity of 412.15%. As a group, research analysts anticipate that RXi Pharmaceuticals will post -1.55 EPS for the current year.
A number of analysts have recently issued reports on RXII shares. ValuEngine raised shares of RXi Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. HC Wainwright set a $3.00 price objective on shares of RXi Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 15th.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.com-unik.info/2018/12/04/rxi-pharmaceuticals-corp-rxii-short-interest-down-47-9-in-november.html.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.
Recommended Story: What is a Reverse Stock Split?
Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.